International Journal of Enhanced Research in Science, Technology & Engineering
ISSN: 2319-7463, Vol. 9 Issue 9, September-2020, Impact Factor: 6.754

Enhancing Antibiotic Efficacy with β-Lactamase Inhibition

Aarti Trehan

Associate Professor, Chemistry Department, Arya Kanya Mahavidyalaya, Shahabad (M), Kurukshetra-136135, India

ABSTRACT

β-lactamase inhibitors are essential tools in the fight against antibiotic resistance. They playcrucial role in addressing antibiotic resistance. Antibiotic resistance occurs when bacteria develop mechanisms to evade the effects of antibiotics, making infections harder to treat. Beta-lactamases are enzymes produced by bacteria that break down and inactivate beta-lactam antibiotics, which include penicillins, cephalosporins, and carbapenems. These antibiotics work by inhibiting cell wall synthesis in bacteria, leading to their death.β-lactaminhibitors bind to the cell wall site and inactivate beta-lactamases, preventing them from breaking down the antibiotics. As a result, the antibiotics can continue to inhibit cell wall synthesis and kill the bacteria. This paper studies the promising β- lactamase inhibitors synthesized to date, as well as their spectrum of activity and current status. Study also focuses on β-lactam/β-lactamase inhibitor combinations that are potentially being used to treat infections. The emergence of these new combinations represents a step forward in the fight against antimicrobial resistance there by enhancing antibiotic efficacy.

Keywords: antibiotic resistance; β-lactamases; β-lactamase inhibitors, β-lactams.

INTRODUCTION

The use of antibiotics has revolutionized modern medicine and has had a profound impact on global health. Since the discovery of penicillin by Sir Alexander Fleming in 1928, antibiotics have become indispensable tools in the fight against bacterial infections. These remarkable substances have saved countless lives, extended life expectancy, and made complex medical procedures, such as surgeries and chemotherapy, much safer. However, the widespread and often indiscriminate use of antibiotics has also given rise to a series of challenges that threaten both their efficacy and the overall health of our planet. In this era of advanced medicine, antibiotics are routinely prescribed to treat bacterial infections ranging from common strep throat to life-threatening conditions like sepsis. Yet, the rise of antibiotic-resistant bacteria, sometimes referred to as "superbugs," poses a growing threat to our ability to combat infectious diseases effectively. Antimicrobial resistance is seriously affecting world health and is growing quickly.

High morbidity and mortality rates are connected with infections brought on by bacteria that are resistant to antibiotics. If steps are not taken to overcome the resistance, this issue could have negative health effects. Despite this expansion of antimicrobial resistance, there are currently no new classes of antimicrobial agents being developed due to the decline in antimicrobial agent development. The majority of antibiotics used today for the human body are β-lactamsantibiotics for bacterial infections (Figure1). They are the most diverse and widely used group of antibiotics in clinical practice.

Figure1: Proportion of prescriptions in the United States for injectable antibiotics by class for years 2004–2014*



*(Data from the IMS MDART Quarterly Database on file at AstraZeneca.)

However, bacteria have developed a number of defense mechanisms to avoid the impact of antibiotics on them. The origin and spread of antibiotic resistance are influenced by a number of variables, including:

- Overuse and incorrect use of antibiotics in human medicine, animal husbandry, and agriculture all significantly contribute to the emergence of resistance. This covers inappropriate dosage, needless prescriptions, and the use of ineffective antibiotics for viral illnesses.
- In healthcare settings, poor sanitation, a lack of hand hygiene, and ineffective infection control practices encourage the spread of resistant bacteria
- Over the past few decades, the discovery and development of new antibiotics has drastically slowed down. By limiting the number of treatments available for infections with resistance, this small pipeline of new medications exacerbates the issue.
- Increased international travel and trade, resistant bacteria can spread quickly across geographical boundaries, posing a threat to world health.

LITERATURE SURVEY

Asummarizedrole of β-lactamase inhibitors in perspective of antibiotic resistance based on the literature [1-5], [10-12]is as follows:

- Restoration of β-Lactam Activity: β-lactamase inhibitors play a vital role in restoring the activity of β-lactam antibiotics against resistant bacteria. Studies have demonstrated the effectiveness of β-lactamase inhibitors in overcoming resistance caused by various types of beta-lactamases.
- Broad-Spectrum Activity: β-lactamase inhibitors exhibit a broad-spectrum activity, inhibiting a wide range of β-lactamases produced by Gram-positive and Gram-negative bacteria.
- Synergy and Enhanced Efficacy: Combination therapy with β-lactamase inhibitors and β-lactam antibiotics has shown synergistic effects, resulting in enhanced antibacterial activity compared to using beta-lactam antibiotics alone. Several studies have reported improved clinical outcomes and increased treatment success rates with combination therapy.
- Reduction of Resistance Selection Pressure: By restoring the activity of β-lactam antibiotics, β-lactamase inhibitors help reduce the selective pressure for the emergence and spread of resistance.
- Clinical Applications and Treatment Options: β-lactamase inhibitors have expanded treatment options for various infections caused by resistant bacteria, including respiratory tract infections, urinary tract infections, intra-abdominal infections, skin and soft tissue infections, and bacteremia.
- Combination Therapies: The use of β-lactamase inhibitors in combination with other antibiotics or antimicrobial agents is an active area of research. Such combination therapies offer potential synergistic effects, overcome specific resistance mechanisms, and provide alternative treatment options for highly resistant bacteria.

It's important to note that the efficacy and effectiveness of β-lactamase inhibitors may vary depending on the specific beta-lactamase enzymes and bacterial strains involved. The rise of antibiotic-resistant bacteria is a major concern, hence researchers are investigating different strategies to address this issue, such as developing beta-lactamase inhibitors that can overcome bacterial resistance mechanisms. These inhibitors can be combined with beta-lactam antibiotics to enhance their effectiveness. Additionally, ongoing research continues to explore new beta-lactamase inhibitors, improve existing ones, and investigate their combinations with other agents to address emerging resistance challenges.

β-lactamases and β- lactamase Inhibitors

The development of substitute antibiotics and tactics to combat antibiotic resistance has been prompted by the substantial challenge posed by the bacterial resistance mechanism in the realm of medicine. Undoubtedly, β-lactam antibiotics are among the most significant medications ever. Since, β-lactams have a very low toxicity to humans and may kill a wide range of bacteria, there is a serious threat from β-lactam resistance. The reactions that involve the cleavage of the β-lactam ring of the antibiotic by β-lactamases of bacteria is the primary mechanism of β-lactam resistance. One of the most frequent causes of bacterial resistance to β-lactam antibiotics, particularly in Gram-negative bacteria, is β-lactamases (BLs) [1]. These are enzymes produced by some bacteria as a defense mechanism against beta-lactam antibiotics. β-lactamases enzymes produced by bacteria break down and inactivate beta-lactam antibiotics, which include penicillins, cephalosporins, and carbapenems. These antibiotics work by inhibiting cell wall synthesis in bacteria, leading to their death. By attaching covalently to the carbonyl moiety of practically all β-lactam antibiotics and hydrolyzing the β-lactam ring, these enzymes can inactivate them as illustrated in following reaction:



Ring Opening of β-lactam by β-lactamase

The range of substrates for β-lactamases has been expanding. Gram-positive bacteria are spread extracellularly, and Gram-negative bacteria are found in the periplasmic region. The bacterial chromosome contains the genes for β-lactamase enzymes, and these genes are frequently present. The two primary classification schemes for β-lactamases: the Ambler classification and the Bush classification based on functionality (substrate and inhibitor moiety) are used to further split β-lactamases into different groups as members of an enzyme family (EC 3.5.2.6). The Bush classification [3] is based on functionality (substrate and inhibition profile), whereas the Ambler classification [2] is based on similarity in amino acid sequence (protein homology). In accordance with the Ambler classification, β-lactamases can be further subdivided into four molecular classes (i.e., A-D). Classes A, C, and D use a serine moiety, whereas class B has a metalloenzymatic zinc ion in its active site. Three main groupings are created using the Bush classification: Group 1, which includes cephalosporinases; Group 2, which includes serine β-lactamases; and Group 3, which includes metallo β-lactamases (MBL).

One of the major mechanisms of β-lactam resistance is the production of β-lactamases. To overcome this obstacle [4], β-lactamase inhibitors have been developed and applied for therapy. The inhibitors change the substrates' capacity to form stable, long-lasting intermediates with β-lactamases, which aids their partner β-lactam in inhibiting its PBP target. Reversible or irreversible methods are both used by BLIs to bind and inactivate β-lactamases [5].Both community and hospital settings have made substantial use of beta-lactamase inhibitors. They are used to treat a variety of infections, including those of the respiratory system, urinary tract, skin, and soft tissues, intra-abdominal infections, and more. These inhibitors increase the likelihood of a good outcome by allowing practitioners to more precisely target resistant bacterial types.

Benefits of β-lactamases inhibitors

In relation to the use of β-lactam antibiotics, β-lactamase inhibitors are particularly important in the fight against antibiotic resistance. Bacteria manufacture enzymes called β-lactamases that render β-lactam antibiotics useless for treating bacterial infections. Some of their significant benefits have been outlined below:

- β-lactamase inhibitors are effective against a wide range of beta-lactamases produced by different bacteria.
- A β-lactamase inhibitor and a β-lactam antibiotic combination therapy have a synergistic effect that increases the antibacterial activity and hence, the clinical outcome.
- Effective treatment with combination therapy reduces the selective advantage for resistant strains, slowing down the development of resistance.
- β-lactamase inhibitors can inhibit additional resistance mechanisms, such as efflux pumps, thereby enhancing the antibiotic's effectiveness against multidrug-resistant bacteria.
- β-lactamase inhibitors can be combined with other antibiotics or antimicrobial agents to create effective combination therapies. This approach is very valuable in the treatment of infections caused by highly resistant bacteria.

Utilizing combination therapy with β-lactamase inhibitors (BLIs) is one tactic to tackle resistance. BLIs are typically prescribed along with their β-lactam antibiotic counterpart because they alone have negligible intrinsic antibacterial action. For instance, clavulanic acid, the first BLI, is more effective when coupled with amoxicillin. Figure 2 displays the chemical structures of some of the BLIs that have been approved by the Food and Drug Administration (FDA).



Figure2: Approved beta- lactam inhibitors

Clavulanate, which was isolated from S. clavuligerus in 1977, was the first β-lactamase inhibitor to be found. Sulbactam and tazobactam were then identified in the 1980s [6-8]. Sulbactam and tazobactam are penicillanic acid sulfones, whereas clavulanic acid is a clavam [9]. Although, they are tiny molecules with a penicillin-like structure, they have only marginal antibacterial activity on their own [10]. They bind β-lactamases permanently. The FDA authorized augmentin (amoxycillin/clavulanate) as the first β-lactam/β-lactamase inhibitor combination [11]. Additionally, type A Ser-β-lactamase is the principal target of the actions of clavulanic acid, sulbactam, and tazobactam, while Class C enzymes are largely unaffected and being virtually inert against Class B and most Class D β- lactmase enzymes [12-15].Avibactam [16] was the first synthetic non-lactam/class A β-lactamase inhibitor. Instead of the β-lactam core seen in tazobactam and sulbactam, it has a diaza-bicyclo octane (DABCO) core [17,18]. The FDA licenced ceftazidime-avibactam in 2015 [19]. Avibactam covalently binds to and inhibits several serine-β-lactamases, including Class A, C, and some Class D [20]. Intriguingly, the covalent inhibition of avibactam occurs in a similar way by opening the avibactam ring, and the reaction is reversible. However, deacylation results in regeneration of the complete molecule rather than hydrolysis and turnover [17].

Further, proteinaceous β-lactamase inhibitors, in particular β-lactamase inhibitory proteins, have also been found and thoroughly investigated over the past few decades. These proteins are effective inhibitors that bind different Class A β-lactamases with high affinity, inactivating the enzymes as a result. It's worth to note that these proteins

successfully attach to and inhibit the clinically relevant KPC-2 enzyme [21-23]. The therapeutic potential of BLIPs is still constrained, nevertheless, by their inability to enter bacterial cells. In this aspect, the protein inhibitors must penetrate the cell wall to get to their β-lactamase intracellular target.

CONCLUSION

This study concludes that at present, the cornerstone of antibiotic therapy against Gram-negative bacterial infections is the combination of three conventional β-lactamase inhibitors with β-lactam antibiotics, such as clavulanic acid, tazobactam, and sulbactam. Since these inhibitors have a similar β-lactam core structure, bacteria have developed methods of resistance to counteract their inhibitory effects. The amino acids at the active site, in particular, are mutated in β-lactamase, which results in poor binding and decreased inhibition. Additionally, small molecule inhibitors used in clinical settings degrade quickly [24]. It has been found that many β-lactamases are not inhibited by the inhibitors that are currently in use. To address these issues, it is necessary to find novel β-lactamase inhibitors. Therefore, β-lactam antibiotics' future depends on continued research, fresh ideas, and a coordinated effort from the medical and scientific fields. To maintain the efficacy of β-lactams and guarantee their continued relevance in treating bacterial infections, it is crucial to address antibiotic resistance, develop novel beta-lactams, and optimize their use through combination therapies and precision medicine.

REFERENCES

[1]. Sandanayaka, V.P.; Prashad, A.S. (2002) Resistance to β-lactam antibiotics: structure and mechanism-based design of β-lactamase inhibitors. Curr. Med. Chem., 9, 1145–1165.
[2]. Ambler, R.P. (1980). The structure of β-lactamases. Philos. Trans. R. Soc. B, 289, 321–331.
[3]. Bush, K.; Jacoby, G.A.; Medeiros, A.A. (1995). A functional classification scheme for β-lactamases and its correlationwith molecular structure. Antimicrob. Agents Chemother. 39, 1211–1233.
[4]. Bonomo, R.A. (2017) β-Lactamases: A focus on current challenges. Cold Spring Harb. Perspect. Med., 7.
[5]. Drawz, S.M.; Bonomo, R.A. (2010). Three decades of β-lactamase inhibitors. Clin. Microbiol. Rev., 23, 160–201.
[6]. Reading, C.; Cole, M. (1977). Clavulanic acid: A beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus.Antimicrob. Agents Chemother. , 11, 852–857.
[7]. English, A.R.; Retsema, J.A.; Girard, A.E.; Lynch, J.E.; Barth, W.E. (1978). CP-45,899, a beta-lactamaseinhibitor that extends the antibacterial spectrum of beta-lactams: Initial bacteriological characterization.Antimicrob. Agents Chemother., 14, 414–419.
[8]. Fisher, J.; Belasco, J.G.; Charnas, R.L.; Khosla, S.; Knowles, J.R., (1980) β-lactamaseinactivation by mechanism-basedreagents. Philos. Trans. R. Soc. Lond. B. Biol. Sci., 289, 309–319.
[9]. Drawz, S.M.; Papp-Wallace, K.M.; Bonomo, R.A., (2014) New β-lactamase inhibitors: A therapeutic renaissance inan MDR world. Antimicrob. Agents Chemother., 58, 1835–1846.
[10]. Wong, D.; van Duin, D., (2017). Novel beta-lactamase inhibitors: Unlocking their potential in therapy. Drugs,77, 615–628.
[11]. Geddes, A.M.; Klugman, K.P.; Rolinson, G.N., (2007). Introduction: Historical perspective and development ofamoxicillin/clavulanate. Int. J. Antimicrob. Agents, 30 (Suppl. 2), S109–S112.
[12]. Buynak, J.D. (2006). Understanding the longevity of the β-lactam antibiotics and of antibiotic/β-lactamase inhibitorcombinations. Biochem. Pharmacol.,71, 930–940.
[13]. Monnaie, D.; Frere, J.M., (1993). Interaction of clavulanate with class C β-lactamases. FEBS Lett., 334, 269–271.
[14]. Page, M.G.P., (2000). β-lactamase inhibitors. Drug Resist. Updat., 3, 109–125.
[15]. Payne, D.J.; Cramp, R.; Winstanley, D.J.; Knowles, D.J., (1994). Comparative activities of clavulanic acid, sulbactam,and tazobactam against clinically important β-lactamases. Antimicrob. Agents Chemother., 38, 767–772.
[16]. Bonnefoy, A.; Dupuis-Hamelin, C.; Steier, V.; Delachaume, C.; Seys, C.; Stachyra, T.; Fairley, M.; Guitton, M.;Lampilas, M., (2004) In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor.J. Antimicrob. Chemother., 54, 410–417.
[17]. Ehmann, D.E.; Jahi´c, H.; Ross, P.L.; Gu, R.F.; Hu, J.; Kern, G.; Walkup, G.K.; Fisher, S.L., (2012). Avibactam is acovalent, reversible, non-β-lactam β-lactamase inhibitor. Proc. Natl. Acad. Sci. USA, 109, 11663–11668.
[18]. Wang, D.Y.; Abboud, M.I.; Markoulides, M.S.; Brem, J.; Schofield, C.J., (2016). The road to avibactam: The firstclinically useful non-β-lactam working somewhat like a β-lactam. Future Med. Chem., 8, 1063–1084.
[19]. Temkin, E.; Torre-Cisneros, J.; Beovic, B.; Benito, N.; Giannella, M.; Gilarranz, R.; Jeremiah, C.; Loeches,B.; Machuca, I.; Jiménez-Martín, M.J., (2017). Ceftazidime-Avibactam as salvage therapy for infections caused bycarbapenem-resistant organisms. Antimicrob. Agents Chemother., 61.

[20]. Lahiri, S.D.; Johnstone, M.R.; Ross, P.L.; McLaughlin, R.E.; Olivier, N.B.; Alm, R.A., (2014). Avibactam and class Cβ-lactamases: Mechanism of inhibition, conservation of the binding pocket, and implications for resistance.Antimicrob. Agents Chemother., 58, 5704–5713.
[21]. Hanes, M.S.; Jude, K.M.; Berger, J.M.; Bonomo, R.A.; Handel, T.M., (2009). Structural and biochemical characterization of the interaction between KPC-2 β-lactamase and β-lactamase inhibitor protein. Biochemistry, 48, 9185–9193.
[22]. Brown, N.G.; Chow, D.C.; Palzkill, T., (2013). BLIP-II is a highly potent inhibitor of Klebsiella pneumoniaecarbapenemase (KPC-2). Antimicrob. Agents Chemother. 57, 3398–3401.
[23]. Nordmann, P., Dortet, L.Poirel, L., (2012). Carbapenem resistance in Enterobacteriaceae: Here is the storm!Trends Mol. Med., 18, 263–272.
[24]. Bush, K., (2018). Game changers: New β-lactamase inhibitor combinations targeting antibiotic resistance inGram-negative bacteria. ACS Infect. Dis., 4, 84–87.